
Publication|Articles|October 10, 2025
- October 2025
- Volume 91
- Issue 10
FDA Approvals for September 2025
Author(s)PT Staff
Key Takeaways
- Recent FDA approvals highlight advancements in oncology, focusing on therapies targeting specific genetic mutations for personalized treatment.
- Expedited review processes by the FDA have enabled quicker access to innovative cancer treatments, improving patient outcomes.
Explore recent FDA-approved drugs from September 2025.
Advertisement
FDA Approvals
Articles in this issue
10 months ago
Recognizing Immunizing Pharmacists in the Community10 months ago
OTC Case Studies: Dry EyeAdvertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Trump Executive Order Recommends Separating MMR Into 3 Shots
2
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
3
Suzetrigine-Based Multimodal Therapy Enables Opioid-Free Recovery in Patients Receiving Surgery
4
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
5




































































































